Your session is about to expire
← Back to Search
Antibody-drug conjugate
CAB-AXL-ADC + PD-1 Inhibitor for Lung Cancer
Phase 2
Recruiting
Research Sponsored by BioAtla, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Adequate renal function
Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 24 months
Awards & highlights
Study Summary
This trial is testing a new cancer drug to see if it is safe and effective for patients with non-small cell lung cancer.
Who is the study for?
Adults over 18 with non-small cell lung cancer (NSCLC) who have measurable disease, are in good physical condition (ECOG status of 0 or 1), and expected to live at least three months. They must have proper blood, kidney, and liver function. Those with severe heart issues, prior specific cancer treatments, recent major surgery, uncontrolled brain metastasis, certain allergies or infections like HIV/hepatitis are excluded.Check my eligibility
What is being tested?
The trial is testing the safety and effectiveness of a new drug called CAB-AXL-ADC for NSCLC patients. It's being compared against PD-1 inhibitors which are a type of immunotherapy that helps the immune system fight cancer cells.See study design
What are the potential side effects?
Possible side effects include allergic reactions related to monoclonal antibody therapy; however specific side effects for CAB-AXL-ADC aren't listed but may be similar to other chemotherapy drugs such as fatigue, nausea, low blood counts increasing infection risk.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My kidneys are working well.
Select...
I am fully active or restricted in physically strenuous activity but can do light work.
Select...
My liver is working well.
Select...
I am 18 years old or older.
Select...
My blood counts are within a healthy range.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 24 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 24 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Confirmed Objective Response Rate (ORR) per RECIST v1.1
Incidence of Adverse Events (AEs)or Serious Adverse Events (SAEs) as assessed by CTCAE v4.03/v5
Secondary outcome measures
Best overall response (BOR)
Disease control rate (DCR)
Duration of response (DOR)
+4 moreTrial Design
2Treatment groups
Experimental Treatment
Group I: CAB-AXL-ADC (BA3011)+PD-1 inhibitorExperimental Treatment2 Interventions
CAB-AXL-ADC (BA3011) with PD-1 inhibitor
Group II: CAB-AXL-ADC (BA3011)Experimental Treatment1 Intervention
CAB-AXL-ADC (BA3011) alone
Find a Location
Who is running the clinical trial?
BioAtla, Inc.Lead Sponsor
6 Previous Clinical Trials
1,168 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- My kidneys are working well.I am fully active or restricted in physically strenuous activity but can do light work.I do not have uncontrolled brain metastases.I have never had a severe allergic reaction to antibody treatments.I am not pregnant or breastfeeding.My liver is working well.I have never been treated with auristatin or similar cancer drugs.I am 18 years old or older.I do not have any serious heart conditions.I have not had major surgery in the last 4 weeks.Patients must have a health condition that can be measured or observed.My blood counts are within a healthy range.I do not have HIV, active hepatitis B, or hepatitis C.
Research Study Groups:
This trial has the following groups:- Group 1: CAB-AXL-ADC (BA3011)+PD-1 inhibitor
- Group 2: CAB-AXL-ADC (BA3011)
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger